Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Enhancement of adipose stem cell quality via Cu-MON: Transcriptome and bioinformatics analysis of normal and diabetic stem cells.

Pang R., Liu K., Liu B., Yang J.

Laboratory Study on Type 2 Diabetes, published in FASEB Bioadv (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
FASEB Bioadv (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40060943
PMCID
PMC11886605
DOI
10.1096/fba.2024-00153
Citations
1

Abstract (original English)

Transplanted adipose stem cells (ASC) have a low survival rate in the body, and there are not many ASC that can be effectively used, which weakens their tissue repair function. Based on this status quo, a new type of copper-based metal-organic network (Cu-MON) was used to pretreat cells to regulate cell activity in order to improve the efficacy of cell therapy or reduce the number of cells used, thus reducing the cost of clinical treatment. Gene expression changes before and after Cu-MON treatment of normal donor adipose stem cells (ND-ASC) and type 2 diabetes mellitus adipose stem cells (T2DM-ASC) were evaluated through RNA sequencing, KEGG and GO enrichment analysis. The results showed that Cu-MON improved ASC cell quality by regulating immune response and promoting paracrine secretion. IL-17 signaling pathway and IL-6, CXCL8, and MMP-9 were key pathways and necessary genes that affected the ability of stem cells. In addition, Cu-MON also improved stem cell antiviral ability through Type I interferon signaling pathway. Our research showed that Cu-MON had improved the cell quality of ASC by regulating immune response, promoting paracrine secretion, and improving antiviral capabilities. This approach to biomaterial pretreatment is fast, convenient, and relatively safe, and provides new strategies for improving the efficiency of cell therapies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research